• Keine Ergebnisse gefunden

Supplementary Table 1 - Example cases for the different repurposing models (based on the IQVIA report) [17]

N/A
N/A
Protected

Academic year: 2022

Aktie "Supplementary Table 1 - Example cases for the different repurposing models (based on the IQVIA report) [17]"

Copied!
4
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Supplementary Table 1 - Example cases for the different repurposing models (based on the IQVIA report) [17]

Repurposing model Example case Description Main value proposition

Repositioning Guanfacine

- Originally used in hypertension - Repositioned to ADHD

Guanfacine offers an important alternative “non-stimulant”

therapeutic option for patients who cannot tolerate stimulant type medication

Reformulation Paclitaxel

- Used in oncology

- Reformulated in an albumin- bound nanoparticle

Enhanced tissue distribution of reformulated paclitaxel resulted in:

- reduction in treatment time from 3 hours to 30 mins, - elimination of the need for pre-medication with steroids

and antihistamines and

- improvement in oncologic response rates and overall survival

Combination (2 oral active compounds)

Oxycodon + Naloxone

- Used to alleviate moderate to severe pain

- Oral combination of 2 off-patent compounds

Oxycodone treats the pain while naloxone counteracts the opioid- induced constipation (common and severe side-effect)

Combination (with new inhaler)

Budesonide + Formoterol + new device

- Used in COPD

- Combination with a new inhaler device

New inhaler reduces common inhaler preparation errors and allows patients to use the inhaler while lying down

(ADHD - Attention Deficit Hyperactivity Disorder, COPD - Chronic Obstructive Pulmonary Disease)

(2)

Supplementary Table 2 - Search syntax for the systematic literature review

Set Search Terms

1 ("added value" OR "me too" OR "value added" OR added-value OR bio-better OR value-added OR repurpos*)

2

(drug[Title/Abstract] OR drugs[Title/Abstract] OR generic[Title/Abstract] OR

generics[Title/Abstract] OR medicat*[Title/Abstract] OR medicin*[Title/Abstract] OR

pharmaceutical[Title/Abstract] OR pharmaceuticals[Title/Abstract] OR product[Title/Abstract] OR products[Title/Abstract] OR therap*[Title/Abstract])

3

("adaptive innovation" OR "drug rediscovery" OR "drug reformulation" OR "drug repositioning"

OR "drug reprofiling" OR "drug re-profiling" OR "drug repurposing" OR "incremental innovation"

OR "marginal innovation" OR "specialty generics" OR "super generics" OR "adapted generics" OR

"customized generics" OR "tailored generics")

4

("value attributes" OR "value drivers" OR "value messages" OR "value proposition" OR "value propositions" OR "value attribute" OR "value driver" OR "value message" OR advantage OR advantages OR benefit OR benefits OR "savings" OR "cost-saving" OR "cost saving" OR "cost reduction" OR "cost-reduction" OR "reduction of costs" OR "multi-criteria decision analysis" OR MCDA OR "multiple criteria decision aiding" OR "multi-criteria decision making" OR "MCDM" OR

"multi-criteria analysis" OR "multi-attribute decision analysis" OR "value framework" OR "value assessment")

(((#1 AND #2) OR #3) AND #4)

(3)

Supplementary Table 3 – Illustrative benefits of value added medicine test cases according to the domains of the core evaluation framework as reported by the IQVIA report [17]

Example case Repurposing model

Ex te n d in g tr e at m e n t o p ti o n s in n ew in d ic ati o n w it h u n m et m e d ic al n e e d In d iv id u al n e e d s/ sp e ci al n e e d s o f p ati e n t (s u b )p o p u la ti o n Ef ca cy / Eff e cti ve n e ss Pa ti e n t sa fe ty a n d to le ra b ili ty P ati en t ex p e ri e n ce r e la te d t o t h e t h e ra p y A d h e re n ce a n d P e rs is te n ce Q u al it y o f lif e P ati en t’ s e co n o m ic b u rd e n Ec o n o m ic a n d h e al th b u rd e n o n in fo rm al ca re gi ve r H e al th c ar e r e so u rc e u ti liz ati o n , c o st s o r ef ci e n cy Te ch n o lo gi ca l i m p ro ve m e n t w it h lo gi sti ca l co n si d e ra ti o n s

guanfacine repositioned

to ADHD ✔ ✔ ✔

paclitaxel reformulation ✔ ✔ ✔

oxycodon

+naloxone oral combination ✔ ✔ ✔ ✔

budesonide +formoterol

+device

combination with

a new inhaler ✔ ✔ ✔

(ADHD - Attention Deficit Hyperactivity Disorder)

Checkmarks indicate the value domains in which the example products offer additional value

(4)

Supplementary Table 4 – A non-exhaustive list of value propositions in each value domain

Domain name Value propositions (non-exhaustive examples) Extending treatment

options in new indication with unmet medical need

- provides greater choice to doctors - limit off-label use of medicines

- provide new treatment option with orphan designation (medicine previously used in a common disease) Individual needs/special

needs of patient (sub)population

- provides greater personalization

- increased number of available dosing options - tailor therapies to specific patient populations - new treatment option for drug resistant patients

Efcacy/Effectiveness

- increased OS/PFS - fewer exacerbations - decreased mortality - delay disease progression - reducing relapse events Patient safety and

tolerability

- improved tolerability - less side-effects

- therapeutic dose-monitoring to avoid toxicity - better on-site dose, with dose reduction Patient experience related

to the therapy

- greater ease of use - reduced pill burden - improved taste

- painless and comfortable application Adherence and Persistence

- improved compliance - reduce medication errors

- sustained drug release with longer treatment effect - enhanced persistence

Quality of life

- improvement of well-being and symptoms - improved functionality

- greater mobility - better mental state - less pain

Patient's economic burden

- shorter self-administration time

- reduced number of missed days at work - enhanced work productivity

Economic and health burden on informal caregiver

- decreased treatment burden for caregiver - less associated out-of-pocket cost of care - less patient supervision is required Health care resource

utilization, costs or efciency

- less associated cost for the healthcare system - positive impact on patient pathway

- reduce drug wastage Technological improvement

with logistical considerations

- improved product stability

- medicine does not require special storage conditions - improved shelf life

Referenzen

ÄHNLICHE DOKUMENTE

N/a: No information available, TV: Tunica vaginalis, TA: Tunica albuginea, TSS: Testis sparing surgery, HSwO: Hemiscrotectomy with Orchiectomy, HS: Hemiscotectomy, TSAO:

2 Path diagram showing the relationship between physician-patient communication, patient satisfaction with treatment decision-making, and patient trust in physicians by

Supplementary Figure 2: 95% confidence intervals distribution of utility value differences in subgroups between the standard of care and remdesivir

In comparison, a North American survey found that a little more than half of orthodontic postgraduate students seem to show the desire to treat patients with special needs, but

We found that, overall, methods with shrinkage on effect modifiers (ie, LASSO, ridge, adaptive LASSO, Bayesian LASSO, and SSVS) performed better (ie, gave better estimates

In this paper, we present a cryptographic EPR access authorization scheme that incorporates patient consent as a basis for granting EPR access to medical teams or practitioners..

Abbreviations: EQOLISE, severe mental illness through supported employment life; IPS, individual and support; PUK, University Hospital for Psychiatry Zurich; SMI, severe mental

After all, highly controversial questions remain unanswered: Which concepts have actually proven successful in implantology in the past decades.. How safe is implant